Details

Last Funding Type

Series A

Last Funding Money Raised

$19M

Industries

Biotechnology,Health Care,Medical,Pharmaceutical

Founded date

Aug 1, 2011

Number Of Employee

11 - 50

Operating Status

Active

PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. Both PI3K and mTOR are clinically validated drug targets in oncology. PIQUR has a secured patent scope protecting many chemical compounds.

PIQUR Therapeutics AG develops breakthrough targeted oncology and dermatology medicines for the treatment of cancers and genetic diseases. The company lead compound bimiralisib focuses on the dual inhibition of the PI3K/mTOR pathway. Both PI3K and mTOR are clinically validated drug targets in oncology and dermato-oncology.

PIQUR Therapeutics was founded in 2011 and is based in Basel, Switzerland.